Hello. At this time, I would like to welcome everyone to the Exact Sciences. Third quarter, 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to Erik ...

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in the year-ago quarter. The figure was wider than the Zacks Consensus ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago.

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...

Exact Sciences Corp ( (EXAS)) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors. Exact Sciences Corp. is a prominent company in ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

Hello. At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings conference call. [Operator instructions] I would now like to turn the call over to Erik ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 ...